Abstract:Interleukin-6 (IL-6) is a multifunctional cytokine involved in essential biological processes, including cell proliferation, differentiation, and maturation, making it a key target in therapeutic development, particularly for COVID-19 treatments. Given its complex biological properties, a thorough understanding of IL-6’s aggregation behavior is critical to optimize the production and stability of anti-IL-6 therapeutic candidates. Recombinant human IL-6 (hIL-6) is typically expressed in Escherichia coli, resulting in significant formation of inclusion bodies, which presents challenges in solubility and refolding. Furthermore, IL-6 exhibits a strong propensity for aggregation, reducing the overall yield of biologically active protein after refolding. This study aimed to elucidate the underlying mechanisms of IL-6 aggregation and to identify refolding conditions that mitigate this phenomenon. Using a combination of SDS-PAGE, size-exclusion chromatography (SEC), Dynamic light scattering (DLS), and circular dichroism (CD) spectroscopy, we analyzed the dimerization and aggregation behavior of IL-6 under varying denaturation and refolding conditions. Our results suggest that IL-6 dimerizes primarily through non-covalent interactions, with its secondary structure largely preserved in the dimeric state. Comparative refolding studies under acidic and guanidine-induced denaturation conditions revealed that the rate of solvent exchange is a critical factor influencing aggregation propensity. These findings provide mechanistic insights into IL-6 aggregation during refolding and highlight strategic parameters for reducing aggregation, thereby enhancing the production yield of refolded IL-6. This work establishes a foundation for refining refolding protocols for IL-6 and potentially other aggregation-prone proteins used in therapeutic applications.

Chemical Synthesis of Interleukin-6 for Mirror-Image Screening

In vitro and in vivo Evaluation of Chemically Synthesized, Receptor-Biased Interleukin-4 and Photocaged Variants

Structure-Based Design of Small-Molecule Inhibitors of Human Interleukin-6

The design of antagonist peptide of hIL-6 based on the binding epitope of hIL-6 by computer-aided molecular modeling.

Discovery and Characterization of a Potent Interleukin-6 Binding Peptide with Neutralizing Activity In Vivo

Unveiling novel insights into human IL-6 - IL-6R interaction sites through 3D computer-guided docking and systematic site mutagenesis

Probing binding mechanism of interleukin-6 and olokizumab: in silico design of potential lead antibodies for autoimmune and inflammatory diseases

Structure-based Virtual Screening and Characterization of a Novel IL-6 Antagonistic Compound from Synthetic Compound Database

Optical Detection of Interleukin-6 Using Liquid Janus Emulsions Using Hyperthermophilic Affinity Proteins

Identification of small molecules as potential inhibitors of interleukin 6: a multi-computational investigation

Development of a synthetic library of humanized nanobodies for targeted IL-6 inhibition

Searching Interleukin 6 Antagonists by Screening Random Peptide Libraries

Total Chemical Synthesis of Human Interferon Alpha‐2b Via Native Chemical Ligation

Semi-synthesis of Interleukin-1Α Via Expressed Threonine Ligation and Native Chemical Ligation-Desulfurization

Expression, Purification and Characterization of Soluble Human Interleukin-6 Receptor Α-Chain and Its Mutant Protein in Escherichia Coli

Synthetic Studies Toward Human Interleukin-5

Exploring the Natural Chemiome to Target Interleukin-6 Receptor (IL-6R) Cytokines: an Atomic Scale Investigation for Novel Rheumatoid Arthritis Drug Discovery

Structure-based Design and Characterization of a Novel IL-6 Antagonist Peptide

Evolution of a bispecific G-quadruplex-forming circular aptamer to block IL-6/sIL-6R interaction for inflammation inhibition

Analytical Characterization of Interleukin-6 Aggregation During Refolding

In Silico Targeting of Interleukin-6 by Natural Compounds